CUREVAC N.V. O.N.
Commented by Carsten Mainitz on July 12th, 2021 | 10:07 CEST
CureVac, XPhyto Therapeutics, Paion - Where are the turning points?
"Opportunity and risk are two sides of the same coin", that is to say, with great potential returns, there is also the risk of incurring significant price losses. The biotechnology sector, in particular, offers investors a broad universe in which to find lucrative investments. We present three exciting ideas below. Who is winning the race?
Read
Commented by André Will-Laudien on July 6th, 2021 | 13:49 CEST
Defence Therapeutics, CureVac, BioNTech - Successful therapy, earn billions!
Since we have a large number of health-threatening issues on the table, there are just as many biotech and pharma companies that have taken up the cause of researching and combating them. Many of them are publicly traded or in the early stages of venture funding. Investors are spoiled for choice; besides good analysis, they need a fair amount of intuition and luck to find the right stock that will truly become a 500-percenter. The cancer research company CEL-SCI recently disappointed, as did the COVID vaccine expert CureVac - both shares ended in a price disaster. The question remains - which horses are the right ones?
Read
Commented by André Will-Laudien on July 1st, 2021 | 10:41 CEST
CureVac, Barrick Gold, Troilus Gold - Now it is important to keep your nerves!
The bull market is maturing a bit more every day. It is no longer young - because it has been running steadily since 2015. Admittedly, it stuttered a bit in March 2020, but the subsequent recovery was all the more violent. There are long-term fundamental trends, so-called megatrends, such as digitalization or e-mobility. At present, we can assume that the mining industry will also boom again in contrast to the crypto world. That is because the medium-term parameters here match the current economic trends. Here is a small selection of well-positioned stocks.
Read
Commented by Carsten Mainitz on June 30th, 2021 | 12:59 CEST
CureVac, Cardiol Therapeutics, MorphoSys - Here it is going powerfully upwards!
Biotech stocks offer investors not only an exciting but also a very profitable investment environment. But the sector is also attractive for traders due to its high volatility. CureVac took a beating recently as the efficacy of its Corona vaccine disappointed. The price of MorphoSys falls despite good news and positive analyst comments. The Canadian Cardiol Therapeutics could be on the verge of a revaluation. Where can the most significant gains be made in the short term?
Read
Commented by Stefan Feulner on June 24th, 2021 | 12:52 CEST
CureVac, Cardiol Therapeutics, Bayer - Where we go from here
Biotechnology has an extraordinary impact on our lives. The perception and appreciation of the future industry of the 21st century has increased significantly in the past year. All thanks due to the race for vaccines against the coronavirus. Yet investing in a biotechnology startup requires patience and a willingness to take risks. The risk that an active ingredient will not work in the end, as the example of CureVac shows, is high. On the other hand, however, investors have the opportunity to multiply their invested capital in the event of successful approval.
Read
Commented by André Will-Laudien on June 18th, 2021 | 12:49 CEST
CureVac, BioNTech, Novavax, XPhyto Therapeutics - The Covid giants and the sellout!
How quickly the tide can turn in the environment of the Corona pandemic can be seen in the vaccine manufacturers and test providers. BioNTech's share price has been rising steadily since the start of the vaccination campaign in Germany, and minor reports of potential side effects are hardly disturbing. In the case of test provider NanoRepro, the bull market of recent months is turning into a total sell-off, with the share losing over 70%. And then there is the Tübingen-based biotech Company CureVac. Delays in approval and a shock on efficacy send the share down by a whole 50% in one day. We take a closer look at the situation.
Read
Commented by Nico Popp on June 15th, 2021 | 13:15 CEST
CureVac, Cardiol Therapeutics, Bayer: Healthcare for the portfolio
Biotechnology and pharmacology offer us great opportunities. For decades, the world has suffered from a few serious diseases: cancer, cardiovascular disease, Alzheimer's, diabetes and others. Where previously only symptoms were treated, there is now the prospect of a cure thanks to new processes. Even if it still takes a little time to reach market maturity: the innovative companies are already on the market, investors can invest.
Read
Commented by Carsten Mainitz on June 14th, 2021 | 11:04 CEST
Adler Modemärkte, Barsele Minerals, CureVac - Watch out: The ABC of price rockets!
News is the fuel for prices. The only question is in which direction the prices will go and how long the fuel will last. With the prospect of a loan from the federal government, the shares of the insolvent textile retailer Adler Modemärkte have made substantial gains since mid-May. In the last week, there was also news at Barsele Minerals and CureVac, which should move the prices in the next few days!
Read
Commented by André Will-Laudien on June 7th, 2021 | 08:32 CEST
CureVac, Cardiol Therapeutics, Formycon, NanoRepro - Pharma stocks with potential!
In Germany, around 231,000 people died as a result of cancer in 2019. As reported by the Federal Statistical Office, cancer was the cause of a quarter of all deaths. This proportion has hardly changed within 20 years, even though the number of cancer deaths has increased by around 10% since 1999. The precise number 1 cause of widespread disease in Germany is cardiovascular disease, such as heart failure, coronary heart disease and myocardial infarction. With 18.2 million deaths, they represented the most common cause of death worldwide in 2019. In Europe, more than 4 million people die each year due to such a disease, 1.4 million of whom are younger than 75. So research continues to be in demand. We look at interesting representatives of the industry.
Read
Commented by Nico Popp on June 1st, 2021 | 10:05 CEST
Defence Therapeutics, CureVac, BioNTech: Vaccine against cancer makes progress
Biotechnology is the map to the holy grail that needs to be found as quickly as possible for many sick people. When the pandemic broke out last year, it accelerated some developments. For example, mRNA technology, which BioNTech and CureVac had already been researching, was successfully launched as a vaccine technology. It is well known that this can be used to develop effective vaccines against coronaviruses and target diseases such as cancer. BioNTech has this option in mind and holds good cards to succeed with it. The young biotech startup Defence Therapeutics has also recently reported its first successes in the fight against cancer.
Read